Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK8 | P45983 | 2/20 | 0.62 |
| ▸ | MAPK9 | P45984 | 2/20 | 0.62 |
| ▸ | MAPK10 | P53779 | 2/20 | 0.62 |
| ▸ | IRAK4 | Q9NWZ3 | 12/20 | 0.36 |
| ▸ | MAP3K12 | Q12852 | 3/20 | 0.36 |
| ▸ | JAK1 | P23458 | 2/20 | 0.35 |
| ▸ | JAK2 | O60674 | 1/20 | 0.35 |
| ▸ | TYK2 | P29597 | 1/20 | 0.35 |
| ▸ | IRAK2 | O43187 | 1/20 | 0.33 |
| ▸ | CLK1 | P49759 | 1/20 | 0.33 |
| ▸ | CLK2 | P49760 | 1/20 | 0.33 |
| ▸ | IRAK1 | P51617 | 1/20 | 0.33 |
| ▸ | HASPIN | Q8TF76 | 1/20 | 0.33 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.33 |
| ▸ | IRAK3 | Q9Y616 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1799166 | 1.00 | MAPK8 (0.62) | MAPK8MAPK9MAPK10IRAK4MAP3K12 | |
| SCHEMBL8167755 | 1.00 | MAPK8 (0.62) | MAPK8MAPK9MAPK10IRAK4MAP3K12 | |
| SCHEMBL1800822 | 0.97 | MAPK8 (0.60) | MAPK8MAPK9MAPK10IRAK4MAP3K12 | |
| SCHEMBL1800824 | 0.97 | MAPK8 (0.60) | MAPK8MAPK9MAPK10IRAK4MAP3K12 | |
| SCHEMBL8172728 | 0.97 | MAPK8 (0.60) | MAPK8MAPK9MAPK10IRAK4MAP3K12 | |
| SCHEMBL1796229 | 0.92 | MAPK8 (0.50) | MAPK8MAPK9MAPK10MAP3K12JAK1 | |
| SCHEMBL8168752 | 0.92 | MAPK8 (0.50) | MAPK8MAPK9MAPK10MAP3K12JAK1 | |
| SCHEMBL1796228 | 0.92 | MAPK8 (0.50) | MAPK8MAPK9MAPK10MAP3K12JAK1 | |
| SCHEMBL12616781 | 0.91 | MAPK8 (0.49) | MAPK8MAPK9MAPK10MAP3K12JAK1 | |
| SCHEMBL12616778 | 0.91 | MAPK8 (0.49) | MAPK8MAPK9MAPK10MAP3K12JAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7951802-B2 | Use of 7-azaindoles in the inhibition of c-Jun N-terminal kinase | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-05-31 | — | — | US | disclosed |
| US-20100069358-A1 | USE OF 7-AZAINDOLES IN THE INHIBITION OF C-JUN N-TERMINAL KINASE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069358-A1 | USE OF 7-AZAINDOLES IN THE INHIBITION OF C-JUN N-TERMINAL KINASE | MAPK7, MAPKAPK5, MAPK13 | MAPK8 33/4885MAPK9 27/4885MAPK10 28/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.